Dendritic Cell Culture at Reduced Temperature
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating mature dendritic cells for immune therapies, such as cancer and infectious disease treatments, face challenges in producing cells with high levels of activated CCR7 and IL-12p70, which are crucial for effective immune response and migration to lymph nodes, while also maintaining low IL-10 production and efficient antigen presentation.
Innovation Solution
A method involving culturing progenitor cells and immature dendritic cells at temperatures below 37°C, specifically 31°C to 36°C, to enhance CCR7 expression, IL-12p70 production, and reduce IL-10 levels, resulting in dendritic cells with improved maturation and immune stimulatory capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard maturation protocol (IL-1beta, IL-6, TNF-alpha, PGE2) is used to generate mature DC, then DC acquire migratory activity and immuno stimulatory activity, but DC produce reduced amounts of IL-12p70
Solution Approach 1:
The patent applies parameter changes by culturing dendritic cells at a reduced temperature of 32°C instead of the standard 37°C. This temperature parameter modification results in DC that simultaneously achieve high migratory activity (through CCR7 expression), strong immuno stimulatory activity, and high IL-12p70 production, thereby resolving the contradiction between these properties
2Quantity of substance
If poly-(I:C) is used to generate DC, then DC produce IL-12p70, but DC express low levels of CCR7 which restricts in vivo migration to lymph nodes
Solution Approach 1:
The patent uses parameter changes by modifying the culture temperature to 32°C, which enables DC to express high levels of CCR7 while maintaining IL-12p70 production. This temperature parameter change resolves the contradiction by allowing simultaneous high expression of both CCR7 (for migration) and IL-12p70 (for immune stimulation)
3Ease of manufacture
If ex vivo manipulation and antigen-loading of autologous DC is performed, then DC can be generated for cancer therapy, but clinical responses are modest and reproducibility is reduced
Solution Approach 1:
The patent applies parameter changes by standardizing the culture temperature at 32°C, which produces DC with consistent and enhanced properties including high CCR7 expression, high IL-12p70 production, and strong immune stimulatory activity. This standardized temperature parameter improves batch-to-batch reproducibility and clinical response reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method generates dendritic cells with increased CCR7 and IL-12p70 expression, reduced IL-10 production, and enhanced immune stimulatory activity, leading to improved clinical responses and stability, addressing the limitations of existing protocols and increasing reproducibility and safety for therapeutic applications.
Implementation Method 1
a method for generating dendritic cells by employing temperatures below 37°C during the development of progenitor cells and immature dendritic cells
Data Source
Figure 1A
Figure 2A~2C
Figure 3
AI summary
The invention relates in certain embodiments to a method for generating dendritic cells by employing temperatures below 37ºC during the development of progenitor cells and immature dendritic cells. In some embodiments the invention relates to populations of dendritic cells and its use.